Epidemiology and risk factors

Current Problems in Cancer

Volumn 26, Issue 4, 2002, Pages 176-181

  Yeo, Theresa Pluth ^a   Hruban, Ralph H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CIGARETTE SMOKING; ENVIRONMENTAL EXPOSURE; FAMILIAL CANCER; GENETIC PREDISPOSITION; HUMAN; PANCREAS CANCER; REVIEW; RISK FACTOR; SURVIVAL RATE; ADENOCARCINOMA; CANCER STAGING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOTHERAPY; MALE; MULTIMODALITY CANCER THERAPY; ONCOGENE; PALLIATIVE THERAPY; PANCREAS; PANCREAS DUCT; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM STAGING; ONCOGENES; PALLIATIVE CARE; PANCREAS; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RISK FACTORS;

EID: 0036661219     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcn.2002.129579     Document Type: Article

References (258)

1. American Cancer Society: facts and figures 2002 : American Cancer Society Atlanta
2. R Greenlee MB Hill-Harmon T Murray M. Thun Cancer statistics, 2001 CA Cancer J Clin 51 2001 15 36
3. JD Ahlgren Epidemiology and risk factors in pancreatic cancer Semin Oncol 23 1996 241 250
4. TA Sohn CJ Yeo JL Cameron L Koniarais S Kaushal R Abrams Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567 579
5. J Birkmeyer A Siewers E Finlayson T Stukel L Lucas I Batista Hospital volume and surgical mortality in the United States N Engl J Med 346 2002 1128 1137
6. S Devesa W Blot B. Stone Recent cancer trends in the United States J Natl Cancer Inst 87 1995 175 182
7. EB Gold SB Goldin Epidemiology of and risk factors for pancreatic cancer Surg Oncol Clin N Am 7 1998 67 91
8. National Center for Health Statistics Health, United States, 2000 with Urban and Rural Chartbook 2001 : Public Health Service Hyattsville, MD
9. DT Silverman M Schiffman J Everhart A Goldstein KD Lillemoe GM Swanson Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer Br J Cancer 80 1999 1830 1837
10. AB Lowenfels P Maisonneuve G Cavallini RW Ammann PG Lankisch JR Andersen Pancreatitis and the risk of pancreatic cancer N Engl J Med 328 1993 1433 1437
11. GJA Offerhaus AC Tersmette GNJ Tytgat PJ Hoedemaeker JP Vandenbroucke Gastric, pancreatic, and colorectal carcinogenesis following remote peptic ulcer surgery. Review of the literature with the emphasis on risk assessment and underlying mechanism Mod Pathol 1 1988 352 356
12. I Mulder MLL van Genugten R Hoogenveen AEM de Hollander HB Bueno-de-Mesquita The impact of smoking on future pancreatic cancer: a computer simulation Ann Oncol 10 1999 S74 S78
13. E. Wynder An epidemiological evaluation of the causes of cancer of the pancreas Cancer Res 35 1975 2228 2233
14. J Everhart D. Wright Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis JAMA 273 1995 1605 1609
15. S Gapstur P Gann W Lowe K Liu L Colangelo A. Dyer Abnormal glucose metabolism and pancreatic cancer mortality JAMA 283 2000 1512 1523
16. DS Michaud E Giovannucci WC Willett GA Colditz MJ Stampfer CS Fuchs Physical activity, obesity, height, and the risk of pancreatic cancer JAMA 286 2001 921 929
17. P Ghadirian G Liu S Gallinger B Schmocker AJ Paradis G Lal Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas Int J Cancer 97 2002 807 810
18. AC Tersmette GM Petersen GJA Offerhaus FC Falatko M Goggins E Rosenblum Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer Clin Cancer Res 7 2001 738 744
19. SS Coughlin EE Calle AV Patel MJ Thun Predictors of pancreatic cancer mortality among a large cohort of United States adults Cancer Causes Control 11 2000 915 923
20. AP Klein GM Petersen TH Beaty JE Bailey-Wilson RH Hruban Statistical evidence for a novel major gene involved in pancreatic cancer Genetic Epidemiology 23 2002 133 149
21. Cancer risks in BRCA2 mutation carriers: the Breast Cancer Linkage Consortium J Natl Cancer Inst. 91 1999 1310 1316
22. KM Murphy KA Brune CA Griffin RH Hruban SE Kern Candidate genes MAP2K4, MADH4, and BRCA2 in familial pancreatic cancer Cancer Res 62 2002 3789 3793
23. M Goggins M Schutte J Lu CA Moskaluk CL Weinstein GM Petersen Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas Cancer Res 56 1996 5360 5364
24. A Borg T Sandberg K Nilsson O Johannsson M Klinker A Masback High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families J Natl Cancer Inst 92 2000 1260 1266
25. HT Lynch RE Brand D Hogg CA Deters RM Fusaro JF Lynch Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome Cancer 94 2002 84 96
26. FM Giardello SB Welsh SR Hamilton Increased risk of cancer in the Peutz-Jeghers syndrome N Engl J Med 316 1987 1511 1514
27. HT Lynch GJ Voorhees S Lanspa PS McGreevy J. Lynch Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study Br J Cancer 52 1985 271 273
28. M Goggins GJA Offerhaus W Hilgers CA Griffin M Shekher D Tang Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+ Am J Pathol 152 1998 1501 1507
29. DC Whitcomb MC Gorry RA Preston W Furey MJ Sossenheimer C Ulrich Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene Nat Genet 14 1996 141 145
30. AB Lowenfels EP Maisonneuve YE Dimagno LK Gates J Perrault DC. Whitcomb International Hereditary Pancreatitis Study Group hereditary pancreatitis and the risk of pancreatic cancer J Natl Cancer Inst 89 1997 442 446
31. RH Hruban GM Petersen PK Ha SE Kern Genetics of pancreatic cancer: From genes to families Surg Oncol Clin N Am 7 1998 1 23
32. MA Eberle R Pfutzer KL Pogue-Geile MP Bronner D Crispin MB Kimmey A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32–34 Am J Hum Genet 70 2002 1044 1048
33. JMW Slack Developmental biology of the pancreas Development 121 1995 1569 1580
34. H. Edlund Pancreas: how to get there from the gut? Curr Opin Cell Biol 11 1999 663 668
35. AL Means SD Leach Lineage commitment and cellular differentiation in exocrine pancreas Pancreatology 1 2001 587 596
36. A Apelqvist H Li L Sommer P Beatus DJ Anderson T Honjo Notch signaling controls pancreatic cell differentiation Nature 400 1999 877 881
37. J Jensen EE Perdersen P Galante J Hald RS Heller M Ishibashi Control of endodermal endocrine development by Hes-1 Nat Genet 24 2000 36 43
38. CA Crisera AS Kadison GD Breslow TS Maldonado MT Longaker GK Gittes Expression and role of laminin-1 in mouse pancreatic organogenesis Diabetes 49 2000 936 944
39. GK Gittes PE Galante D Hanahan WJ Rutter HT Debase Lineage-specific morphogenesis in the developing pancreas: role of mesenchymal factors Development 122 1996 439 447
40. F Miralles P Czernichow R. Scharfmann Follistatin regulates the relative proportions of endocrine versus exocrine tissue during pancreatic development Development 125 1997 1017 1024
41. MF Offield TL Jetton PA Labosky M Ray RW Stein MA Magnuson Pdx-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum Development 122 1996 983 995
42. L St-Onge B Sosa-Pineda K Chowdhury Pax6 is required for differentiation of glucagon-producingα-cells in mouse pancreas Nature 387 1997 406 409
43. SY Song M Gannon MK Washington Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing TGFα Gastroenterology 117 1999 1416 1426
44. IM Meszoely AL Means CR Scoggins SD Leach Developmental aspects of early pancreatic cancer Cancer J 7 2001 242 250
45. EP Sandgren NC Luetteke RD Palmiter RL Brinster DC Lee Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast Cell 61 1990 1121 1135
46. M Wagner FR Greten CK Weber S Koschnick T Mattfeldt W Deppert H Kern G Adler RM Schmid A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease Genes Dev 15 2001 286 293
47. SL Parker T Tong S Bolden PA. Wingo Cancer Statistics CA Cancer J Clin 47 1997 5 27
48. CJ Yeo JL Cameron KD Lillemoe Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients Ann Surg 221 1995 721 733
49. RH Hruban NV Adsay J Albores-Saavedra Pancreatic intraepithelial neoplasia (PanIN): a new nomenclature and classification system for pancreatic duct lesions Am J Surg Pathol 25 2001 579 586
50. J Compagno JE Oertel Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma): a clinicopathologic study of 41 cases Am J Clin Pathol 69 1978 573 580
51. F Sessa C Capella K Kloppel G Zamboni A Scarpa MS Bonato K-ras gene mutation in intraductal neoplasms of the pancreas Lab Invest 70 788 1994 135A
52. G Seidel M Zahurak C Iacobuzio-Donahue Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases Am J Surg Pathol 26 2001 56 63
53. RE Wilentz M Goggins M Redston Genetic, immunohistochemical, and clinical features of medullary carcinomas of the pancreas: a newly described and characterized entity Am J Pathol 156 2000 1641 1651
54. M Goggins GJA Offerhaus W Hilgers Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+ Am J Pathol 152 1998 1501 1507
55. RE Wilentz CH Chung PDJ Sturm K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma Cancer 82 1998 96 103
56. SA Hahn M Schutte ATMS Hoque DPC4, a candidate tumor suppressor gene at human chromosome 18q211 Science 271 1996 350 353
57. RE Wilentz GH Su JL Dai Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic: a new marker of DPC4 inactivation Am J Pathol 156 2000 37 43
58. AL Cubilla PJ Fitzgerald Morphological lesions associated with human primary invasive nonendocrine pancreas cancer Cancer Res 36 1976 2690 2698
59. DJ Brat KD Lillemoe CJ Yeo PB Warfield RH Hruban Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas Am J Surg Pathol 22 1998 163 169
60. RH Hruban GJA Offerhaus SE Kern M Goggins RE Wilentz CJ Yeo Tumor-suppressor genes in pancreatic cancer J Hepatobiliary Pancreat Surg 5 1998 383 391
61. RE Wilentz CA Iacobuzio-Donahue P Argani Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression Cancer Res 60 2000 2002 2006
62. C Caldas SA Hahn RH Hruban MS Redston CJ Yeo SE Kern Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia Cancer Res 54 1994 3568 3573
63. RE Wilentz J Albores-Saavedra M Zahurak Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas Am J Surg Pathol 23 1999 1320 1327
64. LDR Thompson RC Becker RM Przygodzki CF Adair CS Heffess Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of the pancreas Am J Surg Pathol 23 1999 1 16
65. M Tada M Omata M. Ohto Ras gene mutations in intraductal papillary neoplasms of the pancreas: analysis in five cases Cancer 67 1991 634 637
66. H Fujii M Inagaki S Kasai Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas Am J Pathol 151 1997 1447 1454
67. CA Iacobuzio-Donahue D Klimstra NV Adsay DPC-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal carcinomas Am J Pathol 157 2000 755 761
68. JJ Buchino FM Castello HS Nagaraj Pancreatoblastoma: a histochemical and ultrastructural analysis Cancer 53 1984 963 969
69. SC Abraham TT Wu DS Klimstra Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p Am J Pathol 159 2001 1619 1627
70. H Belsky NW Cornell Disseminated focal fat necrosis following radical pancreatico-duodenectomy for acinous carcinoma of head of pancreas Ann Surg 141 1955 556 562
71. DS Klimstra CS Heffess JE Oertel J. Rosai Acinar cell carcinoma of the pancreas: a clinicopathologic study of 28 cases Am J Surg Pathol 16 1992 815 837
72. SC Abraham TT Wu RH Hruban Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway Am J Pathol 160 2002 953 962
73. GM Learmonth SK Price AE Visser M. Emms Papillary and cystic neoplasm of the pancreas—an acinar cell tumour? Histopathology 9 1985 63 79
74. SC Abraham DS Klimstra RE Wilentz Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations Am J Pathol 160 2002 1361 1369
75. RH Hruban ADM van Mansfield GJA Offerhaus DHJ van Weering DC Allison SN Goodman K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization Am J Pathol 143 1993 545 554
76. C Almoguerra D Shibata K Forrester J Martin N Arnheim M. Perucho Most human carcinomas of the exocrine pancreas contain mutant K-ras genes Cell 53 1998 549 554
77. RE Wilentz M Goggins M Redston VA Marcus NV Adsay TA Sohn Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas Am J Pathol 156 2000 1641 1651
78. RE Wilentz DH Chung PDJ Sturn A Musler TA Sohn GJA Offerhaus K-ras mutations in duodenal fluid of patients with pancreas carcinoma Cancer 82 1998 96 103
79. J Boadas J Mora E Urgell P Puig M Roca X Cusso Clinical usefulness of K-ras gene mutation detection and cytology in pancreatic juice in the diagnosis and screening of pancreatic cancer Eur J Gastroenterol Hepatol 13 2001 1153 1159
80. C Caldas SA Hahn RH Hruban MS Redston CJ Yeo SE Kern Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal mucinous cell hyperplasia Cancer Res 54 1994 3568 3573
81. JQ Cheng B Ruggeri WM Klein G Sonoda DA Altomare DK Watson Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proc Natl Acad Sci USA 93 1996 3636 3641
82. C Wallrapp F Muller-Pillasch S Solinas-Toldo P Lichter H Friess M Buchler Characterization of a high copy number amplification of 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene Cancer Res 57 1997 3135 3139
83. C Caldas SA Hahn LT da Costa MS Redston M Schutte AB Seymour Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat Genet 8 1994 27 32
84. M Schutte RH Hruban J Geradts R Maynard W Hilgers SK Rabindran Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Res 57 1997 3126 3130
85. J Yu L Zhang PM Hwang C Rago KW Kinzler B. Vogelstein Identification and classification of p53-regulated genes Proc Natl Acad Sci USA 96 1999 14517 14522
86. H Hermeking C Lengauer K Polyak TC He L Zhang S Thiagalingam 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression Mol Cell 1 1997 3 11
87. SA Hahn M Schutte AT Hoque CA Moskaluk LT da Costa E Rozenblum DPC4, a candidate tumor-suppressor gene at human chromosome 18q211 Science 271 1996 350 353
88. L Zawel JL Dai P Buckhaults S Zhou KW Kinzler B Vogelstein Human Smad3 and Smad4 are sequence specific transcription activators Mol Cell 1 1998 611 617
89. GH Su R Bansal KM Murphy E Montgomery CJ Yeo RH Hruban ACVR1B (ALK4, activin receptor type IB) gene mutations in pancreatic cancer Proc Natl Acad Sci USA 98 2001 3254 3257
90. GH Su W Hilgers M Shekher D Tang CJ Yeo RH Hruban Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene Cancer Res 58 1998 2339 2342
91. DHF Teng WL Perry III JK Hogan M Baumgard R Bell S Berry Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor Cancer Res 57 1997 4177 4182
92. GH Su RH Hruban RK Bansal DS Bova DJ Tang MC Shekher Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers Am J Pathol 154 1999 1835 1840
93. M Goggins GJ Offerhaus W Hilgers CA Griffin M Shekher D Tang Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+ Am J Pathol 152 1998 1501 1507
94. M Goggins M Schutte J Lu CA Moskaluk CL Weinstein GM Peterson Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas Cancer Res 56 1996 5360 5364
95. M Goggins RH Hruban SE Kern BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications Am J Pathol 156 2000 1767 1771
96. CA Iacobuzio-Donahue A Maitra GL Shen-Ong T van Heek R Ashfaq R Meyer Discovery of novel tumor markers of pancreatic cancer using global gene expression technology Am J Pathol 160 2002 1239 1249
97. P Argani C Iacobuzio-Donahue B Ryu M Goggins C Rosty RE Wilentz Mesothelin is expressed in the vast majority of adenocarcinomas of the pancreas: identification of a new cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 2001 3862 3868
98. P Argani C Rosty RE Reiter RE Wilentz SD Murugesan SD Leach Discovery of new markers of cancer through serial analysis of gene expression (SAGE): prostate stem cell antigen (PSCA) is overexpressed in pancreatic adenocarcinoma Cancer Res 61 2001 4320 4324
99. C Rosty T Ueki P Argani M Jansen CJ Yeo JL Cameron Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation Am J Pathol 160 2002 45 50
100. C Rosty L Christa S Kuzdzal WM Baldwin ML Zahurak F Carnot Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology Cancer Res 62 2002 1868 1875
101. Iacobuzio-Donahue CA, Maitra A, Olsen M, van Heek T, Rosty C, Walter K, et al. Exploration of global gene expression of pancreatic adenocarcinoma by cDNA microarray analysis. Am J Pathol [In press].
102. B Ryu J Jones NJ Blades G Parmigiani MA Hollingsworth RH Hruban Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression Cancer Res 62 2002 819 826
103. B Ryu J Jones MA Hollingsworth RH Hruban SE Kern Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers Cancer Res 61 2001 1833 1838
104. CA Iacobuzio-Donahue B Ryu RH Hruban SE Kern Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion Am J Pathol 160 2002 91 99
105. J Ariyama M Suyama K Ogawa T Ikari J Nagaiwa D Fujii The detection and prognosis of small pancreatic carcinoma Int J Pancreatol 7 1990 37 47
106. EK Fishman KM Horton BA Urban Multidetector CT angiography in the evaluation of pancreatic carcinoma: preliminary observations J Comput Assist Tomogr 24 2000 849 853
107. DA Bluemke JL Cameron RH Hruban HA Pitt SS Siegelman P Soyer Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation Radiology 197 1995 381 385
108. T Rosch C Braig T Gain S Feuerbach JR Siewert V Schusdziarra Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography Gastroenterology 102 1992 188 199
109. P Legmann O Vignaux B Dousset AJ Baraza L Palazzo I Dumontier Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography AJR Am J Roentgenol 170 1998 1315 1322
110. D Delbeke DM Rose WC Chapman CW Pinson JK Wright RD Beauchamp Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma J Nucl Med 40 1999 1784 1791
111. J Ariyama M Suyama K Satoh K. Wakabayashi Endoscopic ultrasound and intraductal ultrasound in the diagnosis of small pancreatic tumors Abdom Imaging 23 1998 380 386
112. RA Abrams LB Grochow A Chakravarthy TA Sohn ML Zahurak TL Haulk Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels Int J Radiat Oncol Biol Phys 44 1999 1039 1046
113. TA Brentnall MP Bronner DR Byrd RC Haggitt MB Kimmey Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer Ann Intern Med 131 1999 247 255
114. SA Belinsky KJ Nikula WA Palmisano R Michels G Saccomanno E Gabrielson Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis Proc Natl Acad Sci USA 95 1998 11891 11896
115. E Evron WC Dooley CB Umbricht D Rosenthal N Sacchi E Gabrielson Detection of breast cancer cells in ductal lavage fluid by methylation- specific PCR Lancet 357 2001 1335 1336
116. T Yamada S Nakamori H Ohzato S Oshima T Aoki N Higaki Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features Clin Cancer Res 4 1998 1527 1532
117. HE Mulcahy J Lyautey C Lederrey X qi Chen P Anker EM Alstead A prospective study of K-ras mutations in the plasma of pancreatic cancer patients Clin Cancer Res 4 1998 271 275
118. PA Jones SB Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415 428
119. M Esteller PG Corn SB Baylin JG Herman A gene hypermethylation profile of human cancer Cancer Res 61 2001 3225 3229
120. T Ueki M Toyota T Sohn CJ Yeo JP Issa RH Hruban Hypermethylation of multiple genes in pancreatic adenocarcinoma Cancer Res 60 2000 1835 1839
121. T Ueki M Toyota HG Skinner KM Walter CJ Yeo Issa J-PP Identification and characterization of differentially methylated CpG islands in pancreatic cancer Cancer Res 61 2001 8540 8546
122. T Iwao E Hiyama T Yokoyama A Tsuchida K Hiyama Y Murakami Telomerase activity for the preoperative diagnosis of pancreatic cancer J Natl Cancer Inst 89 1997 1621 1623
123. CA AM Iacobuzio-Donahue GL Shen-Ong T van Heek R Ashfaq R Meyer K Walter Discovery of novel tumor markers of pancreatic cancer using global gene expression technology Am J Pathol 160 2002 1239 1249
124. JJ Byungwoo Ryu NJ Blades G Parmigiani MA Hollingsworth RH Hruban SE Kern Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression Cancer Res 62 2002 819 826
125. P Argani C Iacobuzio-Donahue B Ryu C Rosty M Goggins RE Wilentz Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 2001 3862 3868
126. C Rosty L Christa S Kuzdzal WM Baldwin ML Zahurak F Carnot Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology Cancer Res 62 2002 1868 1875
127. EF Petricoin AM Ardekani BA Hitt PJ Levine VA Fusaro SM Steinberg Use of proteomic patterns in serum to identify ovarian cancer Lancet 359 2002 572 577
128. BL Adam Y Qu JW Davis MD Ward MA Clements LH Cazares Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men Cancer Res 62 2002 3609 3614
129. Exocrine pancreas. AJCC Cancer Staging Manual 6th edition 2002 Springer New York 157 163
130. UICC TNM classification of malignant tumors 4th ed 1987 : Springer Verlag New York
131. Japan Pancreas Society General rules for surgical and pathological studies on cancer of the pancreas 3rd ed 1987 : Kanehara Tokyo
132. J Cujik AG Babiker Pancreatic cancer, diabetes mellitus and gallbladder disease Int J Cancer 43 1989 415 421
133. TA Sohn CJ Yeo JL Cameron CA Iacobuzio-Donahue RH Hruban KD Lillemoe Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathological entity Ann Surg 234 2001 313 322
134. RE Ritts HA Pitt CA19-9 in pancreatic cancer Surg Oncol Clin North Am 7 1998 93 101
135. R Ritts D Nagorney D Jacobsen Comparison of preoperative CA19-9 levels with results of other diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic cancer or gallbladder disease Pancreas 9 1994 707 716
136. C Willett W Daly A. Warshaw CA19-9 is an index of response to neoadjuvant chemoradiation in pancreatic cancer Am J Surg 172 1996 350 352
137. DA Bluemke RA Abrams CJ Yeo Recurrent pancreatic adenocarcinoma: Spiral CT evaluation following the Whipple procedure RadioGraphics 17 1997 303 313
138. CA Iacobuzio-Donahue A Maitra GL Shen-Ong Discovery of novel tumor markers of pancreatic cancer using global gene expression technology Am J Pathol 160 2002 1239 1249
139. P Argani C Iacobuzio-Donahue B Ryu Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 2001 3862 3868
140. P Argani C Rosty RE Reiter Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma Cancer Res 61 2001 4320 4324
141. KM. Horton Multidetector CT and three-dimensional imaging of the pancreas: state of the art J Gastrointest Surg 6 2002 126 128
142. DA Bluemke EK Fishman CT and MR evaluation of pancreatic cancer Surg Oncol Clin North Am 7 1998 103 124
143. M Trede B Rumstadt K Wendl Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors Ann Surg 226 1997 393 407
144. C. Reinhold Magnetic resonance imaging of the pancreas in 2001 J Gastrointest Surg 6 2002 133 135
145. T Rosch R Lorenz C Braig Endoscopic ultrasound in pancreatic tumor diagnosis Gastrointest Endosc 37 1991 347 352
146. H Snady A Cooperman J. Siegel Endoscopic ultrasound compared with computed tomography with ERCP in patients with obstructive jaundice or small peri-pancreatic mass Gastrointest Endosc 38 1992 27 34
147. MF Muller C Meyenberger P Bertschinger Pancreatic tumors: evaluation with endoscopic US, CT and MR imaging Radiology 190 1994 745 757
148. PD Stevens CJ Lightdale The role of endosonography in the diagnosis and management of pancreatic cancer Surg Oncol Clin North Am 7 1998 125 133
149. MJ Wiersema P Vilman M Giovannini Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment Gastroenterology 112 1997 1087 1089
150. MJ Wiersema Endoscopic ultrasonography J Gastrointest Surg 6 2002 129 132
151. PL Baron LE Aabakken DJ Cole Differentiation of benign from malignant masses by endoscopic ultrasound Ann Surg Oncol 4 1997 639 643
152. HR Mertz P Sechopoulos D Delbeke EUS, PET and CT scanning for evaluation of pancreatic adenocarcinoma Gastrointest Endosc 52 2000 367 371
153. F Gress K Gottlieb S Sherman Endoscopic ultrasonography-guided fine-needle aspiration biopsy of suspected pancreatic cancer Ann Intern Med 134 2001 459 464
154. T Inokuma N Tamaki T Torizuka Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer J Nucl Med 36 1995 229 235
155. N. Alazraki Imaging of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography J Gastrointest Surg 6 2002 136 138
156. DM Rose D Delbeke RD Beauchamp 18-fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer Ann Surg 229 1999 729 737
157. CJ Barreiro KD Lillemoe LG Koniaris Diagnostic laparoscopy for periampullary and pancreatic cancer: What is the true benefit? J Gastrointest Surg 6 2002 75 81
158. WA Bemelman LTh de Wit OM van Delden Diagnostic laparoscopy combined with laparoscopic ultrasonography in staging of cancer of the pancreatic head region Br J Surg 82 1995 820 824
159. MP Callery SM Strasberg GM Doherty Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy J Am Coll Surg 185 1997 33 39
160. A Andren-Sandberg CG Lindberg C Lundstedt Computed tomography and laparoscopy in the assessment of the patient with pancreatic cancer J Am Coll Surg 186 1998 35 40
161. KC Conlon E Dougherty DS Klimstra The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy Ann Surg 223 1996 134 140
162. TG John JD Greig DC Carter Carcinoma of the pancreatic head and periampullary region: tumor staging with laparoscopy and laparoscopic ultrasonography Ann Surg 221 1995 156 164
163. C Fernandez-del Castillo AL Warshaw Laparoscopic staging and peritoneal cytology Surg Oncol Clin North Am 7 1998 135 142
164. N Soehendra V. Reynders-Frederix Palliative bile duct drainage—a new endoscopic method of introducing a transpapillary drain Endoscopy 12 1980 8 10
165. DR Lichtenstein DL Carr-Locke Endoscopic palliation for unresectable pancreatic cancer Surg Clin North Am 75 1995 969 988
166. W Molnar AE Stockum Relief of obstructive jaundice through percutaneous transhepatic catheter: a new therapeutic method AJR Am J Roentgenol 122 1974 356 367
167. SL Kaufman Percutaneous palliation of unresectable pancreatic cancer Surg Clin North Am 75 1995 989 999
168. AG Speer PB Cotton RCG Russell Randomized trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice Lancet 2 1987 57 62
169. P Watanapa RCN Williamson Surgical palliation for pancreatic cancer: developments during the past two decades Br J Surg 79 1992 8 20
170. KD Lillemoe Palliative therapy for pancreatic cancer Surg Oncol Clin North Am 7 1998 199 216
171. MH Levy Pharmacology treatment of cancer pain N Engl J Med 335 1996 1124 1132
172. MG Sarr JL Cameron Surgical management of unresectable carcinoma of the pancreas Surgery 91 1983 123 133
173. SM Singh HA Reber Surgical palliation for pancreatic cancer Surg Clin North Am 69 1989 599 611
174. KD Lillemoe JL Cameron JM Hardacre Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial Ann Surg 230 1999 322 330
175. J Copping R Willix R. Kraft Palliative chemical splanchnicectomy Arch Surg 113 1978 509 511
176. KD Lillemoe JL Cameron HS Kaufman Chemical splanchnicectomy in patients with unresectable pancreatic cancer: A prospective randomized trial Ann Surg 217 1993 447 457
177. TA Sohn KD Lillemoe JL Cameron Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s J Am Coll Surg 188 1999 658 669
178. W. Kausch Das Carcinom der Papilla Duodeni und seine radikale Entfeinung Beitrage zur Klinische Chirurgie 78 1912 439 486
179. AO Whipple WB Parsons CR Mullins Treatment of carcinoma of the ampulla of Vater Ann Surg 102 1935 763 779
180. LW Traverso WP Longmire Preservation of the pylorus in pancreaticoduodenectomy Surg Gynecol Obstet 146 1978 959 962
181. CJ Yeo JL Cameron TA Sohn Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome Ann Surg 229 1999 613 624
182. TA Sohn CJ Yeo JL Cameron Resected adenocarcinoma of the pancreas—616 patients: results, outcomes and prognostic indicators J Gastrointest Surg 4 2000 567 579
183. CJ Yeo JL Cameron KD Lillemoe Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma—2: randomized controlled trial evaluating survival, morbidity and mortality Ann Surg 236 2002 355 368
184. Nguyen TC, Sohn TA, Cameron JL, et al. Standard versus radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg [In press].
185. JL Cameron Rapid exposure of the portal and superior mesenteric veins Surg Gynecol Obstet 176 1993 395 398
186. CJ Yeo The Whipple procedure in the 1990s Adv Surg 32 1999 271 303
187. CJ Yeo Surgical management: standard Whipple procedure JL Cameron Atlas of clinical oncology: pancreatic cancer. 2001 BC Decker Hamilton 99 108
188. AJ Pikarsky M Muggia-Sullam A Eid Pancreaticogastrostomy after pancreaticoduodenectomy: a retrospective study of 28 patients Arch Surg 132 1997 296 299
189. J Yamamoto Y Shimamura H Nakahara Simple technique for pancreatogastrostomy and the histological findings of pancreatogastric anastomosis Arch Surg 132 1997 785 788
190. CJ Yeo JL Cameron MM Maher A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy Ann Surg 222 1995 580 592
191. M Trede G Schwall H-D Saeger Survival after pancreaticoduodenectomy: 118 consecutive resections without an operative mortality Ann Surg 211 1990 447 458
192. CJ Yeo JL Cameron TA Sohn Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, outcomes Ann Surg 226 1997 248 260
193. CJ Yeo Management of complications following pancreaticoduodenectomy Surg Clin North Am 75 1995 913 924
194. Sohn TA, Yeo CJ, Cameron JL, et al. Pancreaticoduodenectomy: the role of interventional radiologists in managing patients and complications. J Gastrointest Surg [In press].
195. CJ Yeo JL Cameron Pancreatic cancer: current controversies M Schein L Wise Clinical Controversies in Surgery. 1998 Karger Landes Basel, Switzerland 70 77
196. K Satake H Nishiwaki H Yokomatsu Surgical curability and prognosis for standard versus extended resections for T1carcinoma of the pancreas Surg Gynecol Obstet 175 1992 259 265
197. T Manabe G Ohshio N Baba Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas Cancer 64 1989 1132 1137
198. S Pedrazzoli V DiCarlo R Dionigi Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. A multicenter, prospective, randomized study Ann Surg 228 1998 508 517
199. C Sperti C Pasquali S. Pedrazzoli Ductal adenocarcinoma of the body and tail of the pancreas J Am Coll Surg 185 1997 255 259
200. TP Wade KS Virgo FE Johnson Distal pancreatectomy for cancer: results in US Department of Veterans Affairs Hospitals, 1987-1991 Pancreas 11 1995 341 344
201. MH Kalser SS Ellenberg Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection Arch Surg 120 1985 899 903
202. Gastrointestinal Tumor Study Group A multi institutional comparative trial of radiation therapy alone and in combination with 5-FU for locally unresectable pancreatic carcinoma Ann Surg 189 1979 205 208
203. Gastrointestinal Tumor Study Group Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer Cancer 59 1987 2006 2010
204. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone J Natl Cancer Inst 80 1988 751 755
205. CJ Yeo RA Abrams LB Grochow TA Sohn SE Ord RH Hruban Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival Ann Surg 225 1997 621 636
206. RA Abrams LB Grochow A Chakravarthy TA Sohn M Zahurak TL Haulk Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels Int J Radiat Oncol Biol Phys 44 1999 1039 1046
207. KE Todd B Gloor JS Lane WH Isacoff HA Reber Resection of locally advanced pancreatic cancer after downstaging with continuous infusion 5-fluorouracil, mitomycin-c, leukovorin and dipyridamole J Gastrointest Surg 2 1998 159 166
208. RA Abrams LT Korman CJ Yeo E Jaffee A Chakravarthy ML Zahurak Intensified adjuvant therapy for periampullary (pancreatic, nonpancreatic) adenocarcinoma using irradiation, 5-FU, mitomycin C, leukovorin and dipyridamole (J9625)-updated results ASTRO Proc 48 2000 222a
209. VK Mehta GA Fisher JM Ford HA Oberhelman MA Vierra AJ Bastidas Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer Int J Radiat Oncol Biol Phys 48 2000 1483 1487
210. Y Nukui VJ Picozzi LW Traverso Interferon based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma Am J Surg 179 2000 367 371
211. JH Klinkenbijl J Jeekel T Sahmoud R van Pel ML Couvreur CH Veenhof Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region Ann Surg 230 1999 776 784
212. JP Neoptolemos JA Dunn DD Stocken J Almond K Link H Beger Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial Lancet 358 2001 1576 1585
213. TS Lawrence A Eisbruch CJ McGinn MT Fields DS Shewach Radiosensitization by Gemcitabine Oncology 13 Suppl 5 1999 55 60
214. AW Blackstock SA Bernard F Richards KS Eagle LD Case ME Poole Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer J Clin Oncol 17 1999 2208 2212
215. AW Blackstock MA Tempero D Niedwiecki DR Hollis RJ Mayer JE Tepper Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas Proc ASCO 20 2001 158a [abstract 627]
216. JP Hoffman CJ McGinn C Szarka J Morphis HS Cooper J Wilkes A phase I study of pre-operative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized resectable pancreatic adenocarcinoma Proc ASCO 17 1998 283a [abstract 1090]
217. CJ McGinn DC Smith C Szarka WH Pinover PJ Loehrer JG Morphis A phase I study of gemcitabine in combination with radiation therapy in patients with localized unresectable pancreatic cancer Proc ASCO 17 1998 265a [abstract 1014]
218. CJ McGinn MM Zalupski Combined modality therapy in pancreatic cancer: current status and future directions Cancer J 7 2001 338 348
219. RA Wolff DB Evans DM Gravel R Lenzi PWT Pisters JE Lee Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma Clin Can Res 2246 2001 2246 2253
220. CJ McGinn MM Zalupski I Shureiqi JM Robertson FE Eckhauser DM Smith Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 19 2001 4202 4208
221. MS Talamonti PJ Catalano DJ Vaughn R Whittington RD Beauchamp J Berlin Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity J Clin Oncol 18 2000 3384 3389
222. G Colucci F Giuliani V Gebbia M Biglietto P Rabitti G Uomo Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic cancer: a prospective randomized phase II study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 2002 902 910
223. PA Philip MM Zalupski VK Vaitkevicius P Arlauskas R Chaplen LK Heilbrun Phase II trial of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma Cancer 92 2001 569 577
224. Z Symon M Davis CJ McGinn MM Zalupski TS Lawrence Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic Int J Radiat Oncol Biol Phys 53 2002 140 145
225. CH Crane JL Abbruzzese DB Evans RA Wolff MT Ballo M Delclos Is the therapeutic index better with gemcitabine based chemoradiation than with 5-fluorouracil based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52 2002 1293 1302
226. FR Spitz JL Abbruzzese JE Lee PW Pisters AM Lowy CJ Fenoglio Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas J Clin Oncol 15 1997 928 937
227. JP Hoffman S Lipsitz T Pisansky JL Weese L Solin AB Benson III. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study J Clin Oncol 16 1998 317 323
228. JP Arnoletti JP Hoffman EA Ross SA Kagan NJ Meropol G Freedman Pre-operative chemoradiationin the management of adenocarcinoma of the body of the pancreas Am Surg 68 2002 330 335
229. PWT Pisters RA Wolff NA Janjan KR Cleary C Charnsangavej CN Crane Preoperative paclitaxel and concurrent rapid fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates and event-free outcome J Clin Oncol 20 2002 2537 2544
230. JL Abbruzzese A Rosenberg Q Xiong A LoBuglio W Schmidt R Wolff Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with Gemcitabine in patients with advanced pancreatic cancer Proc ASCO 20 2001 130a [abstract 518]
231. JL Bos Rasoncogenes in human cancer: a review Cancer Res 49 1989 4682 4689
232. RH Hruban AD Van Mansfeld GJ Offerhaus DH VanWeering D Allison SN Goodman K-ras oncogene activation in adenocarcinoma of the pancreas Am J Path 143 1993 545 554
233. SN Khleif S Abrams C Allegra A Bastian E Bergmann S Bernstein The generation of CD4+ and CD8+ T cell responses from patients vaccinated with mutant ras peptides corresponding to the patient's own ras mutation Proc ASCO 16 1997 437a [abstract 1566]
234. ME Wojtowicz MJ Hamilton S Bernstein D McNally S Chatfield M Edison Clinical trial of mutant ras peptide vaccination along with IL-2 or GM-CSF Proc ASCO 20 2000 463a [abstract 1818]
235. MK Gjertsen T Buanes AR Rosseland A Bakka I Gladhaus O Soreide Intradermal ras peptide vaccination with granulocyte-macrophage colony stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma Int J Cancer 92 2001 441 450
236. JJ Lewis S Janetzki PO Livingston D Desantis L Williams D Klimstra Pilot trial of vaccination with autologous tumor derived gp96 heat shock protein -peptide complex (HSPPC-96) in patients with resected pancreatic adenocarcinoma Proc ASCO 19 1999 438a [abstract 1687]
237. DM Pardoll EM Jaffee Cancer vaccines: clinical applications 3rd ed SA Rosenberg The principles and practice of the biologic therapy of cancer. 2000 Lippincott Williams and Wilkens Philadelphia 647 662
238. G Dranoff EM Jaffee A Lazenby P Golumbek H Levistky K Brose Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity Proc Natl Acad Sci USA 90 1993 3539 3543
239. AY Huang PT Golumbek M Ahmadzadeh E Jaffee D Pardoll H. Levitsky Role of bone marrow derived cells in presenting MHC class I restricted tumor antigens Science 264 1994 961 965
240. Y Nakazaki K Tani ZT Lin H Sumimoto H Hibino T Tanabe Vaccine effect of granulocyte-macrophage colony stimulating factor or CD80 gene transduced murine hematopoietic tumor cells and their cooperative enhancement of anti-tumor immunity Gene Ther 5 1998 1355 1362
241. JW Simons EM Jaffee C Weber H Levitsky W Nelson M Carducci Bioactivity of human GM-CSF gene transduced autologous renal vaccines Cancer Res 57 1997 1537 1546
242. EM Jaffee R Hruban B Biedzycki D Laheru K Schepers P Sauter A novel allogeneic GM-CSF secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation J Clin Oncol 19 2001 145 156
243. M Snozl FM Marincola Cancer vaccines: basic principles 3rd ed SA Rosenberg The principles and practice of the biologic therapy of cancer. 2000 Lippincott Williams and Wilkens Philadelphia 617 631
244. D Berd HC Maguire MJ Mastrangelo Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide Cancer Res 46 1986 2572 2577
245. JP Machiels RT Reilly L Emens A Ercolini R Lei D Weintraub Cyclophosphamide, doxorubicin, and Paclitaxel enhance the anti-tumor immune response of GM-CSF secreting whole cell vaccines in tolerized mice Cancer Res 61 2001 3689 3697
246. E Proietti G Greco B Garrone S Baccarini C Mauri M Venditti Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice J Clin Invest 101 1998 429 441
247. AK Nowak BWS Robinson RA Lake Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy Cancer Res 62 2002 2353 2358
248. M Hidalgo SG Eckhardt Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst 93 2001 178 193
249. J Malcolm JH Moore P Eisenberg M Dagenais K Hagan A Fields A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (PTS) with advanced pancreatic Proceedings of the American Society of Clinical Oncology 2000 19
250. JD Evans A Stark CD Johnson F Daniel J Carmichael J Buckels A phase II trial of marimastat in advanced pancreatic cancer Br J Cancer 85 2001 1865 1870
251. SR Bramhall A Rosemurgy PD Brown C Bowry JA Buckels Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial J Clin Oncol 19 2001 3447 3455
252. A. Adjei Blocking oncogenic Ras signaling for cancer therapy J Natl Cancer Inst 93 2001 1062 1074
253. Cohen SJ, Ranganathan S, Lewis N, Rogatko A, Weiner LM, Alpaugh K, et al. Phase II and pharmacodynamic trial of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol [In press].
254. Macdonald JS, Whitehead R, Wade J, Giguere J, Abbruzzese JL. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol [In press].
255. Van Cutsem E, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol [In press].
256. V Grunwald M. Hidalgo The epidermal growth factor receptor: a new target for anticancer therapy Curr Probl Cancer 26 2002 109 164
257. JL Abbruzzese Q Xiong A Lo Buglio W Schmidt R Wolff M Needle Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer Proc Am Soc Clin Oncol 2001
258. Safran J HSchwartz TC King MM Steinhoff C Nauman P Hesketh Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu Proc Am Soc Clin Oncol 2001